Other names: Aduhelm
Categories: Prescription Medication
Description:
Aducanumab s an anti-amyloid antibody approved by the FDA in 2021 for Alzheimer’s disease under accelerated approval, based on its ability to reduce brain amyloid plaques. Its approval is controversial because trials showed mixed evidence of clinical benefit, with only modest slowing of decline in some analyses. The drug carries risks of amyloid-related imaging abnormalities (ARIA), requiring regular MRI monitoring. Due to uncertain benefit and safety concerns, its use is very limited and mostly restricted to clinical trial settings.
Treatment For:
AI generated Summary: Based on the provided information, there are no reviews or ratings available for the treatment 'Aducanumab' against 'Alzheimer's disease'. Without any user feedback or author review, it is not possible to determine the effectiveness of this treatment from the given data.
Aducanumab's FDA approval remains highly controversial due to uncertain clinical benefit despite reducing amyloid plaques. Because of safety concerns and limited evidence, it is reserved for very select patients and is generally available only in the context of a clinical trial setting.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
